Unlike most other bacteria, mycobacteria make fatty acids with the multidomain enzyme eukaryote-like fatty acid synthase I (FASI). Previous studies have demonstrated that the tuberculosis drug pyrazinamide and 5-chloro-pyrazinamide target FASI activity. Biochemical studies have revealed that in addition to C 16:0 , Mycobacterium tuberculosis FASI synthesizes C 26:0 fatty acid, while the Mycobacterium smegmatis enzyme makes C 24:0 fatty acid. In order to express M. tuberculosis FASI in a rapidly growing Mycobacterium and to characterize the M. tuberculosis FASI in vivo, we constructed an M. smegmatis ⌬fas1 strain which contained the M. tuberculosis fas1 homologue. The M. smegmatis ⌬fas1 (attB::M. tuberculosis fas1) strain grew more slowly than the parental M. smegmatis strain and was more susceptible to 5-chloro-pyrazinamide. Surprisingly, while the M. smegmatis ⌬fas1 (attB::M. tuberculosis fas1) strain produced C 26:0 , it predominantly produced C 24:0 . These results suggest that the fatty acid elongation that produces C 24:0 or C 26:0 in vivo is due to a complex interaction among FASI, FabH, and FASII and possibly other systems and is not solely due to FASI elongation, as previously suggested by in vitro studies.
Mycobacterium tuberculosis infects one-third of the world's population, and it is estimated that 1% of the world's population is newly infected with this organism each year (31) . The mycobacterial cell wall is a complex structure that plays a role in both M. tuberculosis virulence and drug resistance (12, 16) . These features of the mycobacterial cell wall are conferred by a wide variety of unique lipids that compose 60% of the cell wall. Mycolic acids (C 74 to C 90 ␣-alkyl ␤-hydroxyl fatty acids) are the major lipid components of the mycobacterial cell wall and the hallmark of mycobacteria and related species (16) . Long-chain saturated fatty acids, which are precursors of cell membrane phospholipids, mycolic acids, and other complex lipids, are generated by the type I fatty acid synthase (FASI) in mycobacteria (4, 6, 16) . Mycobacteria are unusual among prokaryotes in that they possess both FASI (typically found in parasites, fungi, and all higher eukaryotes) and the type II fatty acid synthase (FASII), which is found in most prokaryotes and plants. The multifunctional FASI enzyme is a monomer that contains seven separate domains with catalytic activities, including an active site for the prosthetic group 4Ј-phosphopantetheine of the acyl carrier protein (ACP) (4, 6) . Mycobacterial FASI generates C 16:0 from acetyl coenzyme A (acetylCoA) primers and elongates the molecules to produce C 24:0/26:0 fatty acyl-CoA derivatives, which are the precursors of other fatty acid synthases and polyketide systems (8, 16) . In contrast, FASII elongates the FASI products to produce meromycolate precursors, which are modified and condensed with C 24:0/26:0 to form mycolic acids (8, 16) . In vitro studies have shown that mycobacterial FASI produces a unique bimodal distribution of fatty acids (15, 23) . In addition to C 16:0 , C 24:0 is produced by the rapidly growing organism Mycobacterium smegmatis (23) , and C 26:0 is produced by the slow growers M. tuberculosis and Mycobacterium bovis (15) .
Since fatty acid synthesis in bacteria is essential for cell survival, the enzymes involved in this pathway have emerged as promising targets for antimicrobial agents (14) . The FASII enoyl-ACP reductase was identified as the target of isoniazid and ethionamide, which are first-and second-line tuberculosis drugs (1), as well as a universal bacterial target for triclosan, a consumer antimicrobial agent (13, (18) (19) (20) (21) 28) . The fungal metabolites cerulenin and thiolactomycin target the condensing enzymes of the bacterial FASII pathway (10, 17, 22, 24, 25) . Two studies have shown that 5-chloro-pyrazinamide (5-Cl-PZA) (5, 32) and pyrazinamide (PZA) (32) inhibit M. tuberculosis FASI, indicating that FASI is also a drug target.
The use of PZA, a FASI inhibitor, in tuberculosis chemotherapy has greatly reduced the length of treatment necessary to cure a patient (3, 27) . Therefore, new FASI inhibitors could be useful tools for treating tuberculosis. In order to develop a system that allows quick purification of the large quantities of M. tuberculosis FASI necessary for drug testing or structurefunction studies, we constructed a recombinant M. smegmatis strain in which the native fas1 gene was deleted and replaced with the M. tuberculosis fas1 gene. In the course of analyzing this recombinant M. smegmatis ⌬fasI (attB::M. tuberculosis fas1) strain, which was designated mc 2 2700, we studied the in vivo elongation of C 16:0 by mc 2 2700. The data which are presented in this paper allowed us to challenge the concept that C 16:0 elongation to produce C 24:0 in M. smegmatis or to produce C 26:0 in M. tuberculosis is FASI dependent, as described previously (4, 15, 23) .
MATERIALS AND METHODS
Bacterial strains and media. The M. smegmatis strains used in this study are described in Table 1 . The strains were grown in Middlebrook 7H9 medium (Difco) supplemented with 10% (vol/vol) ADS enrichment (50 g of albumin, 20 g of dextrose, and 8.5 g of sodium chloride in 1 liter of water), 0.2% (vol/vol) glycerol, and 0.5% (vol/vol) Tween 80 or in Mueller-Hinton broth (Difco) supplemented with 0.5% (vol/vol) Tween 80. The solid media used were the media described above with 1.5% (wt/vol) agar added.
MIC determination. The MIC was determined by a broth macrodilution test with an inoculum containing 10 5 CFU of each strain per ml in either Middlebrook 7H9 or Mueller-Hinton broth. The concentrations of 5-Cl-PZA used in these assays were 60, 40, 30, 25, 20, 10, and 5 g/ml; a preparation containing no drug was used as a control. The assay was terminated for each strain independently when the optical density at 600 nm (OD 600 ) in the no-drug tube reached 1 to 1.2. The MIC was defined as the first concentration of drug which resulted in no visible growth (OD 600 , Ͻ0.02).
Determination of generation time. Each strain was grown to an OD 600 of 0.5 in Middlebrook 7H9 broth as described above and was diluted 10-fold to obtain the starting inoculum. The OD 600 of each culture was determined every 120 min for 16 h. In addition, aliquots of each culture were taken at every other time point and plated to determine the number of CFU. The generation time was obtained by plotting the growth curves resulting from both the OD 600 and CFU values.
Transformation experiments. M. smegmatis strains grown at 37°C to the midlog phase (OD 600 , ϳ0.7) were washed twice with 10% cold glycerol and resuspended in cold 10% glycerol (1 ml). A plasmid (1.5 l) was added to each cold cell suspension (150 l) to transform the strain, and the mixture was electroporated by using the following parameters: 2.5 V, 25 F, and 1,000 ⍀. Middlebrook 7H9 broth (1 ml) was added to the suspension, which was incubated at 37°C for 2 h before plating.
Deletion of M. smegmatis fasI by specialized transduction. The allelic exchange substrate was formed by amplification of the 5Ј and 3Ј flanking regions of M. smegmatis fas1 from M. smegmatis genomic DNA. A 850-bp 5Ј flanking region from nucleotide 386 of M. smegmatis fas1 to a noncoding sequence upstream from the fas1 start codon and a 739-bp 3Ј flanking region from nucleotide 7384 of M. smegmatis to nucleotide 8123 of M. smegmatis fas1 were amplified (GenBank accession number AY205337). The amplified flanking regions were cloned with a TA cloning kit into the PCR2.1 vector (Invitrogen) for sequencing and subsequent cloning. The substrate used for allelic exchange was formed by cloning the 5Ј and 3Ј flanking regions of fas1 described above into pJSC285, a cloning vector containing a bacteriophage lambda cos site, a PacI site, and a kanamycin resistance gene flanked by resolvase sites. The allelic exchange substrate on plasmid pYUB978 was packaged into phMSG104 (11) to create phAE978, as previously described (2, 11) . phAE978 was used to transduce mc 2 155 and mc 2 2670 (32). Transduction of M. smegmatis strains. M. smegmatis bacilli were grown to an OD 600 of 0.8 in Luria-Bertani medium supplemented with 0.2% glycerol and 0.1% Tween 80. The cultures (10 ml) were washed twice in mycobacteriophage buffer (50 mM Tris HCl [pH 7.6], 150 mM NaCl, 10 mM, MgCl 2 , 2 mM CaCl 2 ) to remove any traces of the Tween 80 detergent. Adsorption of phAE978 mycobacteriophage to the washed bacilli was carried out at a multiplicity of infection of 10, and the mixture was incubated at 37°C, the nonpermissive temperature, for 30 min. The bacilli were pelleted, plated on Luria-Bertani medium plates containing 25 g of kanamycin per ml, and incubated at 37°C. Kanamycinresistant colonies were screened for allelic exchange by Southern blotting by using PCR products from both M. smegmatis and M. tuberculosis fas1 as probes.
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Construction of mc
2 2700, an M. smegmatis ⌬fas1 mutant containing the M. tuberculosis fasI homologue. Since fatty acid synthases are essential for bacteria, we hypothesized that fas1 is an essential gene for mycobacteria. To delete the M. smegmatis fas1 gene, we first generated mc 2 2670 (Table 1) , an mc 2 155 M. smegmatis derivative containing the M. tuberculosis fas1 gene integrated into the attB site, by using pYUB970, a site-specific integrating cosmid (from a genomic library of M. tuberculosis H37Rv) bearing M. tuberculosis fas1 and its 5Ј and 3Ј flanking regions. The native M. smegmatis fas1 gene was then deleted by specialized transduction (2). The allelic exchange substrate was formed by amplification of the 5Ј and 3Ј flanking regions of M. smegmatis fas1 from M. smegmatis genomic DNA. Kanamycin-resistant (Kan r ) transductants were observed for mc 2 2670 but not for wild-type strain mc 2 155; these results were the results expected for an essential gene that was found to be a drug target (5, 32) . Kan r colonies were screened for allelic exchange by Southern blotting by using PCR products from both M. smegmatis and M. tuberculosis fas1 as probes. The Kan r colonies were found to contain a shifted band that was consistent with allelic exchange with a ⌬fas1 Kan r construct, as shown in Fig. 1 ; this confirmed construction of mc 2 2700, an M. smegmatis strain expressing M. tuberculosis fas1 ( Table 1) .
The ability to exchange M. smegmatis FASI for the M. tuberculosis homologue provided an improved expression system with a rapidly growing, nonpathogenic mycobacterium strain. Moreover, it has been shown previously that M. smegmatis, unlike M. tuberculosis and M. bovis BCG, tolerates multiple copies of M. tuberculosis fas1 (32) . Thus, overexpression of M. tuberculosis FASI under different promoters is feasible in M. smegmatis and could be followed by allelic exchange of the M. smegmatis fas1 gene by using the transduction system which we developed, as shown by the formation of strain mc 2 2700. Growth characteristics and 5-Cl-PZA susceptibility of mc 2 2700. Strain mc 2 2700 differs from the parental M smegmatis strains in several interesting properties. First, mc 2 2700 was found to have a longer generation time (250 min in broth, compared to 210 min for wild-type strain mc 2 155 or mc 2 2670). The generation time was determined by measuring the OD 600 and counting the actual CFU during exponential growth in Middlebrook 7H9 medium and then plotting the resulting growth curves. The slow-growth phenomenon was independent of the medium used. A lower growth rate was also observed in We compared the susceptibilities of wild-type strain mc 2 155, strain mc 2 2670, and strain mc 2 2700 to 5-Cl-PZA. Previously, FASI was identified as a potential drug target for 5-Cl-PZA in M. tuberculosis (32) . Another study confirmed that 5-Cl-PZA inhibits mycobacterial FASI (5). The MIC of 5-Cl-PZA were 10 g/ml for the mc 2 2700 strain and 25 g/ml for mc 2 155 and mc 2 2670, as previously described (32) . The increased susceptibility of mc 2 2700 to 5-Cl-PZA is consistent with the previous finding that M. tuberculosis is more susceptible to 5-Cl-PZA than M. smegmatis (9, 32) . This finding complements the results of a previous study in which the effect of a multicopy fas1 gene on 5-Cl-PZA resistance was described (32) . Multiple copies of M. tuberculosis fas1 conferred only modest resistance to 5-Cl-PZA in M. smegmatis (there was 2.5-fold increase in the MIC), while a single copy of M. tuberculosis fas1 (mc 2 2670) did not confer 5-Cl-PZA resistance in M. smegmatis. In contrast, for a diploid strain containing one extra copy of M. smegmatis fas1, the MIC of this drug was fivefold greater (32) . Taken together, these results show that M. tuberculosis is more susceptible to 5-Cl-PZA than M. smegmatis. Furthermore, the MICs of cerulenin, a FASI (and possibly FASII) inhibitor (22) , and isoniazid, a FASII inhibitor (1, 29, 30) Table 2 and Fig. 2 .
We found that the characteristic C 16:0 -C 24:0 fatty acid bimodal distribution in M. smegmatis was similar for wild-type strain mc 2 155 and the merodiploid fas1 strain mc 2 2670 (Fig. 2) . Surprisingly, the characteristic end product of M. tuberculosis FASI, C 26:0 , was not detected in mc 2 2670, the strain containing both M. smegmatis fas1 and M. tuberculosis fas1. In contrast, mc 2 2700 produced both C 24:0 and C 26:0 . However, C 24:0 was more abundant than C 26:0 in this strain (Table 2 and (15, 23) . Since the M. tuberculosis fas1 gene replaced M. smegmatis fas1 in mc 2 2700, it was predicted that this strain would have a fatty acid profile similar to that of M. tuberculosis or M. bovis BCG strains. The presence of larger amounts of C 24:0 than of C 26:0 despite the deletion of M. smegmatis fas1 suggests that C 16:0 elongation in vivo is not solely determined by FASI activity, as previously shown by in vitro studies in which purified FASI was used (15, 23) .
Unlike the predominant synthesis of C 24:0 over C 26:0 in mc 2 2700, the C 18:0 /C 16:0 ratio was a direct result of the replacement of M. smegmatis fas1 by M. tuberculosis fas1 ( Table 2) . Introducing M. tuberculosis fas1 into a mycobacterial strain increased the amount of C 18:0 synthesized by the strain. The (15) suggest that this fatty acid profile is determined not only by FASI but also by the interaction of FASI with FASII. Previous studies with M. tuberculosis FabH, a ␤-ketoacyl synthase that uses acyl-CoA as its substrate, suggested that this enzymatic system acts as an interface between the type I and type II fatty acid synthase systems by funneling acyl-CoA formed by the FASI system into the FASII elongating acyl-ACP primers (7) . We hypothesize that the differences in the fatty acid profiles of mycobacterial species are due to FASI interactions with FabH and FASII. Further studies of fabH systems in M. smegmatis may delineate the differences in the fatty acid profiles of M. smegmatis and M. tuberculosis. Moreover, the origin of FASI (M. smegmatis or M. tuberculosis) seems to play an important role in the amount of C 18:0 produced by a strain. The C 18:0 /C 16:0 ratio found for mc 2 2700 is similar to the ratio found for M. tuberculosis strains, while the C 18:0 /C 16:0 ratio found for mc 2 2670 is only reminiscent of M. tuberculosis FASI activity in the fas1 merodiploid strain.
M. tuberculosis FASI is an essential enzyme and is unique among bacterial species, and therefore it is an attractive drug target. The ability to express M. tuberculosis fas1 in M. smegmatis should provide a relatively rapid purification system for M. tuberculosis FASI, as previously described (4, 5, 15) , without dependence on expression of the enzyme in Escherichia coli (which has been unsuccessful so far). Moreover, it has been shown previously that M. smegmatis, unlike M. tuberculosis and M. bovis BCG, tolerates multiple copies of M. tuberculosis fas1 (32) . Repeated attempts to transform the slowly growing mycobacteria M. bovis BCG and M. tuberculosis with multiple copies of fas1 yielded no colonies, while M. smegmatis was readily transformed with multiple copies of fas1 (32) . Thus, M. smegmatis is an optimal bacterial system for overexpression of M. tuberculosis FASI. The specialized transduction system for M. smegmatis fas1 described here should allow us to replace M. smegmatis FASI with overexpressed M. tuberculosis FASI under different promoters, which should facilitate large-scale purification. Although the FASI proteins from M. tuberculosis and M. smegmatis exhibit 90% homology, it is preferable to study the FASI protein from the pathogenic organism M. tuberculosis, especially if structure-function studies leading to rationale drug design for M. tuberculosis FASI inhibitors are planned. M. tuberculosis FASI studies should lead to development of new analogs of PZA and new classes of effective FASI inhibitors. In addition, the concern about emergence of drug resistance when universal bacterial sites are targeted should be eliminated as the FASI site is a unique site in bacteria. Improved agents that exhibit activity against mycobacterial FASI may provide new options for treating M. bovis, Mycobacterium avium, and drug-resistant M. tuberculosis infections.
